Stanford Alzheimer's Disease Research Center

斯坦福阿尔茨海默病研究中心

• 批准号: 10409740
• 负责人: Victor Henderson
• 金额: $ 305.19万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10409740
• 关键词: Adult; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Area; Artificial Intelligence; Big Data; Bioinformatics; Biological Markers; Biometry; Blood; Brain; Brain imaging; Cell Line; Cells; Clinical; Clinical Management; Cognitive aging; Communities; Consent; Consultations; Data; Data Set; Dementia with Lewy Bodies; Development; Diagnosis; Disease; Early Diagnosis; Elderly; Family; Feces; Fibroblasts; Foundations; Funding; Future; Goals; Hispanic; Human Resources; Image; Immune; Impaired cognition; Latino; Lewy Bodies; Lewy body pathology; Lewy neurites; Link; Liquid substance; Meninges; Mission; Molecular; Nerve Degeneration; Neurodegenerative Disorders; Parkinson Disease; Participant; Pathogenesis; Pathologic; Persons; Phenotype; Plasma; Population; Proteomics; Research; Research Personnel; Research Support; Research Training; Resistance; Resource Sharing; Resources; Risk; Skin; Solid; Structure; Therapeutic; Training Support; Training and Education; alpha synuclein; brain tissue; cognitive development; community engagement; data management; ethnic minority; high risk; improved; innovation; insight; investigator training; microbiome; motor impairment; multidisciplinary; neuroimaging marker; neuropathology; outreach; pre-clinical; prevent; racial minority population; ranpirnase; recruit; repository; resilience; statistics; stool sample; tool; whole genome

1. SUMMARY (Overall) The National Alzheimer's Project Act establishes an integrated national plan to overcome Alzheimer's disease (AD); develop treatments to prevent, halt, or reverse the course of AD; improve the early diagnosis of AD; and decrease disparities in AD for ethnic and racial minority populations at higher risk for AD. In this context, AD is intended to encompass AD-related dementias, including dementia with Lewy bodies. In support of the goals and research milestones of the National Alzheimer's Project Act, the mission of the Stanford Alzheimer's Disease Research Center (ADRC) is to serve as a shared resource to facilitate and enhance research on AD and the spectrum of cognitive impairment associated with Lewy body (LB) pathology. We follow a strategy of deep phenotyping, believing that critical answers emerge more readily when investigators are able to delve deeply within and across multiple levels of participant data. Healthy adults without cognitive or motor impairment serve both as a comparison (control) population and as a preclinical population in which mechanisms of cognitive aging and clinical transition can be studied. People with Parkinson's disease without cognitive impairment also serve as comparators and as an at-risk transitional population for the development of cognitive impairment linked to LB pathology. ADRC resources will provide investigators with unique opportunities for the parallel study of these two neurodegenerative disorders, enabling insights into pathogenesis, preclinical diagnosis, transitions, resistance and resilience, and therapeutic approaches. Aims of the Stanford ADRC are to (1) provide an administrative structure that advances the mission of the center; (2) develop and maintain human resources for studies of the AD spectrum and the LB spectrum of cognitive impairment, as well as cognitive aging; (3) make available well-characterized brain tissues, brain-derived biospecimens, and quantitative molecular data derived from high-content imaging of brain tissues; (4) make available participant biospecimens and high-content biospecimen data; (5) provide structural, functional, and molecular neuroimaging biomarkers in support of research on AD-spectrum cognitive impairment, LB-spectrum cognitive impairment, and cognitive aging; (6) provide for the management of Stanford ADRC data, prepare research datasets, provide high-level biostatistical consultation for ADRC investigators, and support research on big data using tools from biostatistics, bioinformatics, and artificial intelligence; (7) with our community partners, provide respectful, culturally sensitive outreach and provide opportunities for education, training, and research participation for healthy adults, people with AD-spectrum and LB-spectrum disorders, and their families. Stanford ADRC outreach and community engagement extends particularly to urban Hispanic/Latino older adults, an important Bay Area population, which is under-represented in AD-related research; and (8) support the training of investigators and future leaders in the field of AD and related dementia.

1. 概要（总体） 《国家阿尔茨海默病项目法案》制定了一项克服阿尔茨海默病的综合国家计划 （广告）;开发预防、阻止或逆转 AD 病程的治疗方法；提高 AD 的早期诊断；和 减少 AD 风险较高的少数族裔和种族人群的 AD 差异。在这种背景下，AD 旨在涵盖 AD 相关痴呆，包括路易体痴呆。支持目标 以及国家阿尔茨海默病项目法案的研究里程碑，斯坦福阿尔茨海默病中心的使命 疾病研究中心 (ADRC) 将作为共享资源促进和加强 AD 研究 以及与路易体 (LB) 病理相关的一系列认知障碍。我们遵循以下策略 深层表型分析，相信当研究人员能够深入研究时，更容易出现关键答案 深入并跨越多个级别的参与者数据。没有认知或运动能力的健康成年人 损伤既可以作为比较（对照）人群，也可以作为临床前人群，其中 可以研究认知衰老和临床转变的机制。患有帕金森病的人没有 认知障碍也可以作为比较对象，并作为发展的高危过渡人群。 认知障碍与 LB 病理有关。 ADRC 资源将为调查人员提供独特的 对这两种神经退行性疾病进行并行研究的机会，使人们能够深入了解 发病机制、临床前诊断、转变、抵抗力和恢复力以及治疗方法。目标 斯坦福 ADRC 将 (1) 提供一个行政结构来推进该中心的使命； (2) 开发和维护 AD 谱系和 LB 认知谱系研究的人力资源 损害以及认知老化； (3) 提供特征良好的脑组织、脑源性 生物样本和来自脑组织高内涵成像的定量分子数据； (4) 使 可用的参与者生物样本和高内涵生物样本数据； (5) 提供结构、功能和 支持 AD 谱认知障碍、LB 谱研究的分子神经影像生物标志物 认知障碍和认知衰老； (6) 提供斯坦福ADRC数据的管理，准备 研究数据集，为 ADRC 研究人员提供高水平生物统计咨询，并支持研究 使用生物统计学、生物信息学和人工智能工具研究大数据； (7) 与我们的社区 合作伙伴，提供尊重、文化敏感的外展活动，并提供教育、培训和培训机会 健康成年人、AD 谱系和 LB 谱系疾病患者及其他们的研究参与 家庭。斯坦福大学 ADRC 的外展和社区参与特别扩展到城市西班牙裔/拉丁裔 老年人是湾区的重要人群，但在 AD 相关研究中代表性不足；和（8） 支持 AD 和相关痴呆症领域的研究人员和未来领导者的培训。